Best Small Cap Stocks To Invest In 2015

Best Small Cap Stocks To Invest In 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Dan Carroll]

  Few biotechs were hit as hard as Achillion Pharmaceuticals (NASDAQ: ACHN  ) this week, however. Achillion makes up around 2% of the weight of the SPDR Biotech ETF, and its 7.5% loss this week was a major reason for the fund's fall. This stock has failed to capitalize on the markets' surge this year, losing 10% year-to-date. The company only recently named a new CEO, lifting its former R&D head and chief science officer to the top job. Achillion's still in the developmental stage of its life and thus produces no revenue, and the company's cash burn makes it seem likely that more share dilution is on its way as the company looks to advance its hepatitis-C pipeline over the coming years. Until Achillion produces some meaningful results from that pipeline, this stock! will remain a risky play in an already risky space.

• [By Lisa Levin]

  Achillion Pharmaceuticals (NASDAQ: ACHN) rose 14.34% to $9.65 after the company reported that it has achieved 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-small-cap-stocks-to-invest-in-2015-2.html